AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Sympathetic Nerve Activity
Description: Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry
Description: Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous occlusion plethysmography
Description: Venous occlusion plethysmography was used to assess non-invasively blood flow.
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood samples were drawn in the morning after 12h overnight fasting.
Study NCT03463226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometers for Handgrip Strength
Description: Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
Study NCT02246985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable bread only
Description: A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
Study NCT02246985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plain bread with vegetable mayonnaise
Description: Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
Study NCT02246985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable bread with plain mayonnaise
Description: A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
Study NCT04429594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling at J0, M6, M12, M24, M36, M48, M60
Study NCT00582452 — intervention group
Intervention type: OTHER
Intervention: Telephone survey
Description: Telephone survey
Study NCT00404183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Hydrocodone/Acetaminophen
Description: 2 tablets BID
Study NCT00404183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets BID
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Operator Role Real TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Operator Role Real TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.
Study NCT01283425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: Heaters for single use and a permanent control unit.
Study NCT04037956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tubeless NOSES
Description: The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
Study NCT04037956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic radical resection
Description: The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
Study NCT01954173 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy
Description: Undergo conformal radiation therapy
Study NCT02128100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
Study NCT00373061 — intervention group
Intervention type: DRUG
Intervention: Xolair®
Description: This being an observational study, the study protocol does not specify any dose regimen.
Study NCT04615585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe vera after SRP
Description: Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
Study NCT04615585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
Study NCT01567228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA GIS (enhanced electronic medical record)
Description: An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
Study NCT02370576 — intervention group
Intervention type: OTHER
Intervention: rating scale application
Description: Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application
Study NCT04610697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
Study NCT04610697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
Study NCT04294745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal infiltration
Description: Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
Study NCT04294745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Standard technique of mandibular nerve block
Study NCT00450385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
Study NCT00450385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
Study NCT00450385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
Study NCT00450385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
Study NCT00450385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
Study NCT04600310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ULTRAPREP
Description: ULTRAPREP device for reducing OR prep times.
Study NCT04600310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No Intervention
Description: Conventional skin preparation technique
Study NCT01286831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GW642444
Description: Single 200μg dose of \[14C\]GW642444 given on Day 1.
Study NCT03877081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Administration of oral probiotics with 2 doses a day
Study NCT03877081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral placebo with 2 doses a day
Study NCT00400153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent Respimat (20 mcg)
Study NCT00400153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT MDI (36/206 mcg)
Study NCT00400153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat (20 mcg/100 mcg)
Study NCT00400153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via corresponding inhaler for blinding purposes
Study NCT04473573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spartan Cube CYP2C19 System
Description: Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
Study NCT02933515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga and occupational therapy
Description: group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
Study NCT00658333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Acid (EC-MPA)
Study NCT00658333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Study NCT00658333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MMF
Study NCT00658333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo EC-MPA
Study NCT01057264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Abraxane
Description: Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
Study NCT01057264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
Study NCT01057264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV on Day 1 of 21 day cycle
Study NCT01057264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
Study NCT02660554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction (PCR)
Description: Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
Study NCT03445676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABHR directly on gloves
Description: HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
Study NCT03445676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ABHR directly on gloves
Description: HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
Study NCT03787433 — intervention group
Intervention type: DEVICE
Intervention: ARC - Assisted Rehabilitation Care
Description: ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings.
Study NCT02498223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiment protocol
Description: the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances.
Study NCT03396549 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: new sham tDCS
Description: 1 ch TCT transcranial stimulator
Study NCT03396549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: 1 ch TCT transcranial stimulator
Study NCT03089567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: 5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
Study NCT03089567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: 38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
Study NCT01225068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
Study NCT01225068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
Study NCT01506791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study NCT01506791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study NCT02231203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Study NCT02231203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 infusions, 2 ml/kg, one the night before operation and one the day after operation
Study NCT01784471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magic Foot™
Description: Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
Study NCT02597595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spirulina
Description: oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
Study NCT00124540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Study NCT00124540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo resembling misoprosotl
Study NCT04054713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Acetic acid chromoendoscopy
Description: Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
Study NCT04054713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Seattle protocol
Description: Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
Study NCT00149214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 1
Description: Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study NCT00539721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant Dose 2
Description: Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver Role Real TMS
Description: In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice.
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Operator Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Operator Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Receiver Role Sham TMS
Description: In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice.
Study NCT01030133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: All Participants Operator Role
Description: All participants in Operator Role (Receiving real or sham TMS)